Fusion Antibodies (LON:FAB) Shares Up 5.3% – Here’s Why

Fusion Antibodies plc (LON:FAB) was up 5.3% on Tuesday . The stock traded as high as GBX 13.50 and last traded at GBX 12.90. Approximately 927,426 shares changed hands during trading, an increase of 97% from the average daily volume of 471,367 shares. The stock had previously closed at GBX 12.25.

Fusion Antibodies Stock Up 5.3%

The firm has a 50 day simple moving average of GBX 13.46 and a two-hundred day simple moving average of GBX 14.13. The company has a quick ratio of 2.36, a current ratio of 1.80 and a debt-to-equity ratio of 92.42. The stock has a market capitalization of £16.13 million, a P/E ratio of -8.60 and a beta of 1.22.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.